Congress trades

Sarepta Therapeutics, Inc. (SRPT)

NASDAQ · Healthcare · 17 congress trades · last filed 1 year ago

17
Congress disclosures shown
35d
Median delay on the congress disclosures
of the 45 day limit
11 buys·6 sells
Purchases and sales in the disclosures shown
Get a push when a member of Congress trades SRPT.

Free on iOS and Android.

About Sarepta Therapeutics, Inc.

from the company's filings and listing, as of Oct 21, 2026
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
Michael E. Severino
Employees
835
Listed since
Jun 4, 1997
Market value
$2.0B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$1.30
Dividend yield
-

www.sarepta.com

Earnings

6 reported quarters · next on Nov 4, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Aug 5, 2026-$0.05$0.22$401.3M$366.4MEPS miss, GAAPRevenue beat
Q1 FY2026reported May 6, 2026$3.16$0.98$730.8M$474.2MEPS beatRevenue beat
Q4 FY2025reported Feb 25, 2026-$3.58-$1.03$442.9M$369.6MEPS missRevenue beat
Q3 FY2025reported Nov 3, 2025-$1.80-$0.73$399.4M$335.8MEPS miss, GAAPRevenue beat
Q2 FY2025reported Aug 6, 2025$2.02$0.83$611.1M$530.7MEPS beatRevenue beat
Q1 FY2025reported May 6, 2025-$4.60-$0.87$744.9M$687.5MEPS miss, GAAPRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 24, 2026
ExecutiveSalaryStock awardsOtherTotal
Douglas S. IngramChief Executive Officer$1.2M$6.0M$669K$7.8M
Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Operations$753K$2.6M$1.1M$4.5M
Ian M. EstepanPresident, Chief Operating Officer$741K$2.6M$1.1M$4.4M
Ryan H. WongExecutive Vice President, Chief Financial Officer$480K$2.2M$553K$3.2M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$341.3M18,994,958+28.7%18.02%
State Street Corp$160.2M8,916,090+34.8%8.49%
Vanguard Portfolio Management LLC$150.5M8,377,470+26.2%7.95%
Two Sigma Investments, LP$82.6M4,598,735+0.1%4.36%
Vanguard Capital Management LLC$82.5M4,591,755+0.3%4.36%
First Trust Advisors LP$78.5M4,365,951+5.6%4.14%
AQR Capital Management LLCCliff Asness$76.9M4,325,689-32.8%4.10%
Geode Capital Management, LLC$49.8M2,771,758+39.4%2.63%
Erste Asset Management GmbH$45.5M2,568,945-13.5%2.44%
Marshall Wace, LLP$39.6M2,206,022+204.3%2.09%
Morgan Stanley$39.6M2,202,641-15.2%2.09%
Aberdeen Group PLC$39.4M2,194,948-5.3%2.08%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Know when the next SRPT filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Congress trades in SRPT

17 disclosures of 17 on record · median 35d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Gilbert Ray Cisneros, Jr.StockSale$1,001 - $15,000-67.5%After the saleS&P 500 +41.0% · -108.5 pts vs S&P 500Apr 14, 2025May 6, 202522d
Josh GottheimerJointStockPurchase$1,001 - $15,000-83.6%S&P 500 +69.2% · -152.8 pts vs S&P 500Jul 14, 2023Aug 21, 202338d
Josh GottheimerJointStockSale$1,001 - $15,000-86.3%After the saleS&P 500 +74.1% · -160.4 pts vs S&P 500Jun 13, 2023Jul 11, 202328d
Daniel S. GoldmanStockSale$15,001 - $50,000-87.4%After the saleS&P 500 +85.6% · -173.0 pts vs S&P 500Apr 10, 2023May 19, 202339d
Josh GottheimerJointStockPurchase$1,001 - $15,000-88.6%S&P 500 +87.9% · -176.6 pts vs S&P 500Mar 6, 2023Apr 20, 202345d
Daniel S. GoldmanStockPurchase$15,001 - $50,000-88.6%S&P 500 +87.9% · -176.6 pts vs S&P 500Mar 6, 2023Apr 17, 202342d
Daniel S. GoldmanStockSale$1,001 - $15,000-85.8%After the saleS&P 500 +87.1% · -172.9 pts vs S&P 500Jan 31, 2023Feb 24, 202324d
Josh GottheimerJointStockSale$1,001 - $15,000-85.9%After the saleS&P 500 +117.1% · -203.0 pts vs S&P 500Nov 6, 2020Dec 9, 202033d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-87.2%S&P 500 +124.7% · -211.8 pts vs S&P 500Sep 14, 2020Oct 14, 202030d
Gilbert Ray Cisneros, Jr.StockSale$1,001 - $15,000-88.9%After the saleS&P 500 +138.2% · -227.1 pts vs S&P 500Jun 10, 2020Jul 17, 202037d
Josh GottheimerJointStockPurchase$1,001 - $15,000-86.6%S&P 500 +139.7% · -226.3 pts vs S&P 500Dec 13, 2019Jan 6, 202024d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-78.7%S&P 500 +159.4% · -238.1 pts vs S&P 500Oct 10, 2019Nov 15, 201936d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-78.8%S&P 500 +156.7% · -235.5 pts vs S&P 500Oct 11, 2019Nov 15, 201935d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-85.7%S&P 500 +164.8% · -250.5 pts vs S&P 500Apr 9, 2019May 14, 201935d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-86.8%S&P 500 +172.9% · -259.7 pts vs S&P 500Mar 11, 2019Apr 16, 201936d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-87.3%S&P 500 +172.0% · -259.4 pts vs S&P 500Feb 26, 2019Mar 8, 201910d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000-88.3%S&P 500 +172.2% · -260.5 pts vs S&P 500Feb 27, 2019Mar 8, 20199d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

Every Congress trade in SRPT, filterable by party, chamber, type and account.

Questions

Which members of Congress have traded SRPT?

Gilbert Ray Cisneros, Jr., Josh Gottheimer and Daniel S. Goldman disclosed SRPT transactions in the filings shown here.

How quickly are SRPT trades disclosed?

Congressional disclosures took a median of 35 days, against the 45 the STOCK Act allows.

How to read a STOCK Act filing

WHAT THE FILING ACTUALLY SAYS

$A range, not an amount. Members disclose a band such as $1,001 to $15,000. The band is the filing, and we do not narrow it.
45Up to 45 days after the trade, lawfully. The delay column counts calendar days from the transaction to its publication. Inside 45 days is within the law.
OPAn option names the underlying. A contract on a company is described using that company's name, so it can read like a share purchase. Those rows say otherwise.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track